ELTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ELTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2024-12-12), Elicio Therapeutics's 5-Day RSI is 55.85.
The industry rank for Elicio Therapeutics's 5-Day RSI or its related term are showing as below:
For the Biotechnology subindustry, Elicio Therapeutics's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Elicio Therapeutics's 5-Day RSI falls into.
The formula for calculating RSI is:
RSI | = | 100 | – | [ 100 | / | ( 1 + Average Gain | / | Average Loss )] |
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elicio Therapeutics (NAS:ELTX) 5-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Thank you for viewing the detailed overview of Elicio Therapeutics's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.
Yekaterina Chudnovsky | director | C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
Robert R Ruffolo | director | |
Peter Demuth | officer: Chief Scientific Officer | C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
Assaf Segal | director | C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
Annette Matthies | officer: Chief Business Officer | ONE KENDALL SQUARE, BUILDING 1400 WEST, SUITE 14303, CAMBRIDGE MA 02139 |
Robert Connelly | director, officer: CEO, President and Director | 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102 |
Julian Adams | director | C/O GAMIDA CELL, 673 BOYLSTON STREET, 4TH FLOOR, BOSTON MA 02116 |
Christopher Haqq | officer: See Remarks | C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Carol Gail Ashe | director | C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3 |
Brian Piekos | officer: Chief Financial Officer | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Karen J Wilson | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Gilbert S Omenn | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Gregory S Curhan | officer: See Remarks | 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108 |
Itzhak Goldberg | officer: See Remarks | 51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553 |
John F. Neylan | officer: See Remarks | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
From GuruFocus
By Marketwired • 08-28-2023
By GlobeNewswire • 09-27-2023
By Marketwired • 10-16-2024
By Marketwired • 08-28-2024
By Marketwired • 05-15-2024
By Marketwired • 12-03-2024
By Marketwired • 09-17-2024
By Marketwired • 10-11-2023
By sperokesalga sperokesalga • 06-06-2023
By Marketwired • 11-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.